Knight Therapeutics (TSE:GUD) Upgraded by Raymond James to Moderate Buy Rating

Raymond James upgraded shares of Knight Therapeutics (TSE:GUD) to a moderate buy rating in a research report released on Friday morning,Zacks.com reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

A number of other equities research analysts also recently commented on GUD. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the company from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th.

Knight Therapeutics Stock Performance

GUD opened at C$5.37 on Friday. Knight Therapeutics has a 1-year low of C$5.07 and a 1-year high of C$6.23. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The business has a 50 day moving average price of C$5.70 and a two-hundred day moving average price of C$5.73. The company has a market capitalization of C$543.50 million, a price-to-earnings ratio of -26.85, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insiders Place Their Bets

In related news, Director Samira Sakhia purchased 20,000 shares of Knight Therapeutics stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Company insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.